Harrow announces relaunch of TRIESENCE for vitrectomy visualization, inflamation

Harrow (HROW) announced the relaunch of TRIESENCE, triamcinolone acetonide injectable suspension, 40 mg/mL, a preservative-free synthetic corticosteroid that is approved by the U.S. Food and Drug Administration FDA for visualization during vitrectomy and for the treatment of ocular inflammatory conditions that are unresponsive to topical corticosteroids. In commenting on the announcement, Mark L. Baum, Chairman and Chief Executive Officer of Harrow, said, “We are very excited to have brought TRIESENCE back to the U.S. market, providing ophthalmologists access to a trusted FDA-approved product that has benefited millions of Americans. Accomplishing this required rebuilding the entire TRIESENCE supply chain and involved a global collaboration between Harrow and technical experts from our partners around the world. We are grateful for this team’s dedication and commitment, without which we would not have achieved this success.”